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Abstract
Background: Activins are members of the TGF-β family of ligands that have multiple biological functions in
embryonic stem cells as well as in differentiated tissue. Serum levels of activin A were found to be elevated in
pathological conditions such as cachexia, osteoporosis and cancer. Signaling by activin A through canonical
ALK4-ACVR2 receptor complexes activates the transcription factors SMAD2 and SMAD3. Activin A has a strong
affinity to type 2 receptors, a feature that they share with some of the bone morphogenetic proteins (BMPs). Activin
A is also elevated in myeloma patients with advanced disease and is involved in myeloma bone disease.
Results: In this study we investigated effects of activin A binding to receptors that are shared with BMPs using
myeloma cell lines with well-characterized BMP-receptor expression and responses. Activin A antagonized BMP-6
and BMP-9, but not BMP-2 and BMP-4. Activin A was able to counteract BMPs that signal through the type 2
receptors ACVR2A and ACVR2B in combination with ALK2, but not BMPs that signal through BMPR2 in combination
with ALK3 and ALK6.
Conclusions: We propose that one important way that activin A regulates cell behavior is by antagonizing
BMP-ACVR2A/ACVR2B/ALK2 signaling.
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Lay abstract
Activin A and bone morphogenetic proteins (BMPs) be-
long to a large group of signaling molecules denoted the
transforming growth factor (TGF)-β superfamily. The li-
gands in this family bind to different complexes of type
1 and type 2 receptors, and initiate signaling through
intracellular SMAD proteins. Usually, activin A and
BMPs signal through SMAD2/3 and SMAD1/5/8, re-
spectively. Activation of one type of SMAD protein may
result in completely different outcome in cells compared
with activation of the other type of SMAD protein.
Activin A binds strongly to the type 2 receptors
ACVR2A and ACVR2B that they share with some of the
BMPs. Using myeloma cell lines with well-characterized
BMP-receptor expression and responses, we found that
activin A inhibited signaling by BMP-6 and BMP-9 by
competing for type 2 receptors. BMP-2 and BMP-4 pre-
fer another type 2 receptor, named BMPR2, and were
not inhibited by activin A. Thus, one ligand in the TGF-
β superfamily may inhibit signaling by another ligand,
indicating that the relative abundance of ligands deter-
mine outcome of signaling.
Background
Members of the transforming growth factor (TGF)-β
superfamily are involved in regulating diverse biological
processes, including apoptosis, proliferation, organ de-
velopment and bone formation. The ligands are divided
into subgroups based upon their activation of different
SMAD proteins and include TGF-β, bone morpho-
genetic proteins (BMPs), growth differentiation factors
(GDFs), activins and inhibins. Ligands of the TGF-β fam-
ily signal through type 1 and type 2 receptors that are
conserved single transmembrane serine/threonine kinase
receptors. These receptors dimerize upon ligand binding
and the specificity of the ligand is commonly determined
by the binding to the type 2 receptor. Thereafter the
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appropriate type 1 receptor is recruited. The formation
of a ligand-receptor complex enables phosphorylation of
the type 1 receptor which initiates downstream signaling
via intracellular SMAD proteins. In most cases, TGF-β
and activins signal through SMAD2/3, whereas BMPs
signal through SMAD1/5/8, however this is determined
by which of the type 1 receptors that is present in the
ligand-bound signaling complex. For example TGF-β
can activate both SMAD2/3 and SMAD1/5/8 after bind-
ing heteromeric complexes that contain both ALK5 and
ALK1 type 1 receptors [1].
Activin A regulates multiple biological functions such as
hormonal homeostasis, inflammation, and bone homeo-
stasis by stimulating osteoclastogenesis and inhibiting the
formation of osteoblasts. Activin A is produced by many
cells in the immune system, including osteoblasts as well
as by CD14+ osteoclast precursors [2,3]. Previously it has
been shown that Activin A has an impact on macrophage
polarization and may function either as a pro- or as an
anti-inflammatory mediator [4]. In patients suffering from
multiple myeloma activin A was upregulated in patients
with advanced disease and the levels correlated with pres-
ence of bone disease [5,6]. Activin A primarily binds to
the type 1 receptors ALK4 or ALK7 in complex with
ACVR2A or ACVR2B, causing activation of SMAD2 or
SMAD3 [7]. However, there are reports of activin A bind-
ing to and signaling through ALK2 and BMPR2 [8,9]. Fol-
listatin is a natural antagonist of activin A which
prevents activin A from interacting with its receptors
[10,11]. Follistatin is also produced by osteoblasts along
with activin A and the ratio between activin A and fol-
listatin was decreased in mineralizing cultures com-
pared to control cultures, indicating the existence of a
negative feedback mechanism [2].
Using myeloma cell lines as a model system, we show
that activin A antagonizes BMP-6 or BMP-9-signaling
through ACVR2A/ACVR2B/ALK2, but not BMP-2 or
BMP-4-signaling through BMPR2/ALK3 or BMPR2/ALK6.
Results
We have previously shown that BMPs mediated growth
arrest and apoptosis in myeloma cells by activation of
SMAD1/5/8 and consequent downregulation of MYC
[12]. We wanted to study the impact of activin A on
SMAD1/5/8-signaling and, hence, on myeloma cell
growth and survival. First we measured the mRNA expres-
sion of the type 1 activin A receptors ALK4 and ALK7 in
eight different myeloma cell lines. All the tested cell lines
expressed both receptors albeit to varying degrees, imply-
ing that canonical activin A signaling could take place in
these cells (Figure 1A). However, using CellTiter-Glo,
which is a sensitive assay for cell proliferation, activin A
did not influence the growth rate of any of the myeloma
cell lines even after three days of treatment with activin A
(data not shown). Nevertheless, treatment with either
TGF-β or activin A led to phosphorylation of SMAD2, as
shown here for the IH-1 and INA-6 myeloma cell lines
(Figure 1B). Thus, canonical activin A- and TGF-β-
signaling can take place in myeloma cells. In contrast to
activin A, BMP-9 induced apoptosis in INA-6 and IH-1
cells as previously shown (Figure 1C-D) [13]. Interestingly,
the effect of BMP-9 on cell viability was blunted in the
presence of activin A (Figure 1C-D). BMP-induced apop-
tosis in myeloma cell lines is dependent on SMAD1/5/8-
phosphorylation [12]. Experiments were thus performed
to investigate whether activin A also prevented BMP-
induced phosphorylation of SMAD1/5/8. Indeed, acti-
vin A treatment lead to inhibition of BMP-9-induced
SMAD1/5/8-phosphorylation in both INA-6 and IH-1
cells (Figure 1E-F). INA-6 and IH-1 are both IL-6-
dependent cell lines. To rule out that the effects of acti-
vin A were directly related to IL-6-dependency, we also
looked at an IL-6-independent cell line, JJN-3. As ex-
pected, in this cell line activin A also inhibited BMP-6-
and BMP-9-induced phosphorylation of SMAD1/5/8
(Additional file 1: Figure S1).
In contrast to activin A, TGF-β did not antagonize BMP-
induced effects in IH-1 cells (Additional file 2: Figure S2A).
Treatment with BMP-9 in the presence of activin A or
TGF-β showed that activin A, but not TGF-β, inhibited
BMP-induced SMAD1/5/8-activation (Additional file 2:
Figure S2B) suggesting that activation of SMAD2 was not
sufficient to inhibit BMP-9. Furthermore, SB431542, an in-
hibitor of SMAD2/3 activation [14], was used to test if sig-
naling through SMAD2 or SMAD3 was necessary for the
activin A mediated inhibition of BMP-9. SB431542 treat-
ment inhibited activin A- and TGF-β-induced SMAD2-
phosphorylation (Additional file 2: Figure S2C), but did
not influence the effect of activin A on BMP-induced
growth inhibition in IH-1 or INA-6 cells (Figure 2A-B).
Taken together, we concluded that activin A inhibited
BMP-9 signaling in myeloma cells through a mechanism
that was independent of activation of SMAD2 through
ALK4 or ALK7.
IH-1 cells were further used to compare the effects of
activin A on signaling by BMP-2, −4, −6 and −9 using
the CellTiter-Glo assay. Interestingly, activin A inhibited
both BMP-6- and BMP-9-signaling, but had little or no
effect on BMP-2- or BMP-4-signaling (Figure 2C). As
expected, addition of follistatin blunted the inhibitory ef-
fect by activin A on BMP-6 and BMP-9. The finding that
activin A inhibited only two out of four BMPs suggested
that the mechanism did not involve the inhibitory
SMADs, SMAD-6 or SMAD-7, which are shared by the
BMPs, but rather one or more specific receptors. We hy-
pothesized that the antagonizing effect of activin A on
BMP-6 and BMP-9 could be caused by competition for
receptors that are shared by activin A and BMP-6 or
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BMP-9. BMP-6 and BMP-9 signals through the type 1
receptor ALK2 in myeloma cells, whereas BMP-2 and
BMP-4 do not signal in cells that express ALK2, but lack
ALK3 and ALK6, as is the case for the INA-6 myeloma
cell line [12,13,15,16].
Moreover, it was shown that BMP-2 and BMP-4 pref-
erentially use the type 2 receptor BMPR2, whereas
BMP-6 and BMP-7 use ACVR2A and ACVR2B [17].
Thus, ALK2, ACVR2A and ACVR2B are candidate me-
diators of the antagonizing effects of activin A on BMP-
6 and BMP-9 signaling in myeloma cells. We therefore
mapped the expression of receptors that could be of
relevance to both BMP and activin A signaling in INA-6
and IH-1 cells. Both cell lines expressed the type 1 re-
ceptor ALK2 and the type 2 receptors ACVR2A and
ACVR2B (Figure 3A).
We went on to see which of these receptors could also
bind activin A. By using soluble chimeric Fc-receptors
we found that the effects of BMP-6 on cells were not af-
fected by any of the candidate receptors ALK2, ACVR2A
or ACVR2B, whereas BMP-9 activity was inhibited by
the type 2 receptors ACVR2A and ACVR2B (Figure 3B).
This was observed even though we have shown that
BMP-6 and BMP-9 both signal through ALK2 in these
cells [12,13]. A likely reason for this is that the affinity of
either of these BMPs to ALK2 alone is weak and not
Figure 1 Activin A inhibited BMP-9-induced apoptosis. (A) The expression of the type I receptors ALK4 and ALK7 in eight human myeloma cell
lines was determined using QRT-PCR. The delta delta Ct method using GAPDH as housekeeping gene was used to determine the relative levels of
mRNA compared to the expression of ALK7 in cell line JJN-3 (Ct-value = 33) which was set to 1. (B) Phosphorylation of SMAD2 was determined using
immunoblotting in INA-6 and IH-1 cells treated with activin A (10 ng/mL) or TGF-β (5 ng/mL) for 4 hours. GAPDH was used as loading control. INA-6
(C) and IH-1 cells (D) were treated for three days with activin A (10 ng/mL) and the indicated concentrations of BMP-9 before cell viability was
determined by flow cytometry using annexin V/PI labeling. Cells that were negative for both annexin V and PI were considered viable. Phosphorylation
of SMAD1/5/8 or SMAD2 was determined using immunoblotting in INA-6 (E) and IH-1 cells (F) treated with activin A (10 ng/mL) and/or BMP-9
(0.5 ng/mL) for one, six and 24 hours. GAPDH was used as loading control.
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enough to cause binding. Since BMP-6 was not affected
by any of the soluble Fc-receptors, we could use this
assay to study the effects of one receptor at a time with
regards to activin A binding. We hypothesized that acti-
vin A could bind stronger than BMP-6 to ALK2,
ACVR2A or ACVR2B. Indeed, we found that activin A’s
inhibitory effect against BMP-6 was prevented by the
addition of soluble ACVR2A or ACVR2B (Figure 3C),
indicating that activin A could compete with BMP-6 for
binding to ACVR2A and ACVR2B. To directly show
that activin A competed with BMP-9 for binding to
ACVR2A and ACVR2B, we measured the binding of
BMP-9 in the absence and presence of activin A to re-
combinant receptors in a cell-free assay. The presence of
activin A inhibited BMP-9 binding to isolated receptors
in a dose dependent manner (Figure 3D). Furthermore,
this inhibition of BMP-9 binding by activin A could be
reverted by adding follistatin (Figure 3E). The reduction
of 15 ng/mL BMP-9 binding to about 50% by addition of
15 ng/mL activin A suggests that BMP-9 and activin A
have approximately similar affinities for these receptors.
Discussion
BMPs are extremely potent in inducing myeloma cell
death and thus, myeloma cells must have ways to escape
the tumor suppressing effects of BMPs. The main find-
ing reported here is that activin A, by sharing receptors
with BMP-6 and BMP-9, but not BMP-2 and BMP-4,
may inhibit BMP-6 and BMP-9-induced apoptosis in
myeloma cells. In myeloma cells, BMP-6- and BMP-9-
induced activation of SMAD1/5/8 through ACVR2A/
ACVR2B/ALK2 was inhibited by activin A treatment.
Furthermore, we showed directly that activin A and
BMP-9 competed for binding to isolated recombinant
ACVR2A and ACVR2B.
The activin- and BMP-receptors are shared by multiple
ligands. Moreover, ACVR2A, ACVR2B and ALK2 are ubi-
quitously expressed and knowledge about regulation of
signaling through these receptors might have general im-
plications, for instance in bone homeostasis in myeloma
patients. It has been shown that elevated levels of activin
A were associated with poor prognosis and severity of
bone disease [5,6]. Moreover, activin A inhibited SMAD1/
Figure 2 Activin A inhibited cell death induced by BMP-6 and BMP-9, but not by BMP-2 and BMP-4. IH-1 (A) and INA-6 cells (B) were treated with
the indicated concentrations of BMP-9, activin A (10 ng/mL) and the inhibitor SB431542 (5 μM) for three days before cell growth was determined using
the CellTiter Glo assay. Relative luciferase units (RLU) reflected the amount of ATP in each well, represented as mean ± SEM from three independent
experiments. P-values were determined by T-test (*P < 0.05, **P < 0.01). (C) IH-1 cells were treated for three days with activin A (10 ng/mL), BMP-2
(5 ng/mL), BMP-4 (2.5 ng/mL), BMP-6 (25 ng/mL), BMP-9 (0.5 ng/mL) and follistatin (625 ng/mL) before cell growth was determined as in (A).
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5/8 activity, but the role of different BMPs in bone
homeostasis is still unclear. Thus, it is currently not
known which BMP is the most important for bone forma-
tion in vivo and to what extent inhibition of BMP activities
plays a role for formation of osteolytic lesions in myeloma
patients. It could be hypothesized that BMP-6 and BMP-9
which both are affected by activin A are important for
bone homeostasis in myeloma patients. Further experi-
ments are needed to address this issue.
Unlike most BMPs, activin A has been shown to have
a strong affinity for type 2 receptors. Thus, when decoy
receptors for ACVR2A or ACVR2B were used in clinical
trials, activin A signaling was inhibited with improved
anemia and bone disease [18,19]. It is therefore tempting
to speculate that the effects on anemia and bone disease
also could be due to increased BMP-6 or BMP-9 activity,
due to activin A inhibition.
The repertoire of type 1 and type 2 receptors, as well as
type 3 receptors and other co-factors expressed on a given
cell determine the effects of a given TGF-β superfamily
ligand. It is still unclear which combination of type 1 and
type 2 receptors are used by the different BMPs. It could
be redundancy in the system, so that any one of the type 2
receptors could be used by many of the BMPs, or there
may be a specific type 2 receptor needed for a specific
combination of BMP and type 1 receptor. These are unre-
solved questions and the answers to these would provide
more insight into how to regulate activin A activity in a
more controlled and specific manner.
Another determining factor for activin A signaling is
the presence of natural antagonists. The best known an-
tagonist of activin A is follistatin which binds to activin
A with high affinity and also may cause its degradation
[10,11]. Thus, the ratio between follistatin and activin A
Figure 3 Activin A competes with BMP-6 and BMP-9 in binding to the type II receptors ACVR2A and ACVR2B. (A) Expression of the type II
receptors ACVR2A and ACVR2B in INA-6 and IH-1 cells were determined using QRT-PCR. The delta delta Ct method using GAPDH as housekeeping
gene was used to determine the relative levels of mRNA compared to the expression of ACVR2A in INA-6 (Ct-value = 33) which was set to 1. (B) INA-6
cells were treated with BMP-6 (50 ng/mL) or BMP-9 (0.25 ng/mL) for three days in the presence of the soluble Fc-receptors ACVR1/ALK2, BMPR2,
ACVR2A or ACVR2B (5 μg/mL) and cell growth was determined using the CellTiter Glo assay. Relative luciferase units (RLU) reflected the amount of ATP
in each well, represented as mean ± SEM from three independent experiments. P-values were determined by T-test (*P < 0.05, **P < 0.01). (C) INA-6 cells
were treated with BMP-6 (25 ng/mL) with or without activin A (10 ng/mL) and soluble Fc-receptors (5 μg/mL) where indicated and cell growth was
determined as in (B). (D) Soluble Fc-receptor ACVR2A and ACVR2B (1 μg/mL) was coated in wells and treated with BMP-9 (15 ng/mL) and different
concentrations of activin A (1.5-50 ng/mL). Bound BMP-9 was expressed as absorbance (OD) using BMP-9 DuoSet detection reagents. Shown are mean ±
SEM values from three independent experiments. P-values were determined by T-test (*P < 0.05, **P < 0.01). (E) Soluble receptors were coated into plates
as in (D) and treated with BMP-9 (15 ng/mL), activin A (15 ng/mL) and different concentrations of follistatin (300–1000 ng/mL). Binding of BMP-9 was
determined as in (D).
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should determine activin A’s ability to inhibit BMP-6 or
BMP-9, both with regards to myeloma cell apoptosis and
to osteoblastogenesis.
Conclusions
The main finding presented here is that activin A regu-
lated cell behavior by antagonizing BMPs that signal
through ACVR2A/ACVR2B/ALK2. Our results provide
further knowledge on the mechanisms behind activin A
function on the cellular level. Due to an increasing num-
ber of clinical trials using different inhibitors of activin
A function, this information may be useful to under-
stand and to avoid possible side effects.
Methods
Cell lines and reagents
The human multiple myeloma cell lines INA-6, ANBL-6,
CAG and JJN-3 were kind gifts from Dr. M. Gramatzki
(University of Erlangen-Nurnberg, Erlangen, Germany),
Dr. D. Jelinek (Mayo Clinic, Rochester, MN, USA), Dr. J.
Epstein (University of Arkansas for Medical Sciences,
Little Rock, AR, USA) and Dr. J. Ball (University of
Birmingham, UK), respectively. RPMI-8226 and U266
were from American Type Culture Collection (Rockville,
MD, USA). IH-1 [20] and KJON were established in our
laboratory. INA-6 and ANBL-6 cells were grown in 10%
heat inactivated fetal calf serum (FCS) in RPMI-1640
(RPMI) supplemented with recombinant human interleu-
kin (IL)-6 (1 ng/mL). IH-1 and KJON cells were main-
tained in 10% (IH-1) or 5% (KJON) heat inactivated
human serum (HS) (Department of Immunology and
Transfusion Medicine, St. Olav’s University Hospital,
Trondheim, Norway) in RPMI and IL-6 (2 ng/mL). CAG,
JJN-3, RPMI-8226 and U266 were grown in RPMI supple-
mented with 10, 10, 20 or 15% FCS, respectively. Cells
were cultured at 37°C in a humidified atmosphere con-
taining 5% CO2. For experiments 2% HS in RPMI was
used, with IL-6 (1 ng/mL) added for IL-6 dependent cells.
All recombinant human proteins (Activin A, follistatin,
TGF-β, BMP-2, BMP-4, BMP-6, BMP-9, ALK2-Fc,
BMPR2-Fc, ACVR2A-Fc, ACVR2B-Fc) were from R&D
Systems (R&D Systems Europe Ltd., Abingdon, UK), ex-
cept IL-6 (Biosource, Camarillo, CA, USA) and SB431542
(Sigma-Aldrich, St Louis, MO, USA).
Cell viability
To measure changes in cell viability, cells were stained
using the Apotest FITC kit (Nexins Research, Kattendijke,
the Netherlands). The cells were incubated with annexin
V FITC (0.2 μg/mL in annexin binding buffer) for 1 h on
ice. Propidium iodide (PI) (1.4 μg/mL) was added 5 min
prior to data acquisition using an LSRII flow cytometer
(BD Biosciences). Cells negative for both annexin V and PI
staining were considered viable.
Cell proliferation
CellTiter-Glo (Promega, Madison, WI, USA) measures
ATP-levels in cells by use of luciferase and was used to de-
termine relative cell proliferation. Cells were seeded in 96-
well optical plates and treated as indicated. CellTiter-Glo
reagent was added according to the manufacturer’s protocol
and luminescence was determined using Victor 1420 multi-
label counter (PerkinElmer Inc., Waltham, MA, USA).
Western blotting
Cells were treated as indicated, washed with ice cold
phosphate-buffered saline (PBS) and lysed for 30 minutes
on ice. The lysis buffer contained 1% Nonidet P40 (NP-
40) (Sigma-Aldrich), 150 mM NaCl, 50 mM Tris–HCl
(pH 7.5), protease inhibitor cocktail (Roche, Basel,
Switzerland), 1 mM Na3VO4 and 50 mM NaF. Samples
were separated on NuPAGE Bis-Tris gels with MOPS
running buffer (Invitrogen, Carlsbad, CA, USA). Gels
were blotted onto nitrocellulose membranes, blocked
with 5% nonfat dry milk in Tris-buffered saline with
0.01% Tween 20 (TBS-T) and incubated over night with pri-
mary antibodies as indicated. Primary antibodies used were:
phospho-SMAD1/5/8 (RRID:AB_331672, Cat# 9511 L, Cell
Signaling Technology, Beverly, MA, USA), phospho-
SMAD2 (RRID:AB_1587251, Cat# 04–953, Millipore A/S,
Oslo, Norway) and GAPDH (RRID:AB_2107448, Cat#
Ab8245, Abcam, Cambridge, UK). Blots were washed in
TBS-T before incubation for one hour with horseradish
peroxidase conjugated secondary antibodies (Dako Cytoma-
tion, Glostrup, Denmark). The blots were washed thor-
oughly with TBS-T before bands were detected using
SuperSignal West Femto (Thermo Fisher Scientific,
Waltham, MA, USA) as luminescence substrate and
Licor Odyssey FC (LI-COR Biosciences, NE, USA).
QRT-PCR
Total RNA was isolated using the High Pure RNA Isola-
tion Kit (Roche Applied Science, Mannheim, Germany),
and complementary DNA (cDNA) was synthesized using
the High Capacity RNA-to-cDNA kit (Applied Biosystems,
Foster City, CA, USA). PCR was performed using StepOne
real-time PCR System and Taqman Gene Expression As-
says (Applied Biosystems). The Taqman assays used were:
ACVR1B/ALK4 (Hs00244715_m1), ACVR1C/ALK7 (Hs0
0899854_m1), ACVR1/ALK2 (Hs00153836_m1), ACVR2A
(Hs00155658_m1), ACVR2B (Hs00609603_m1), and GAPDH
(Hs99999905_m1). The comparative Ct method was used
to estimate relative changes in receptor expression using
GAPDH as housekeeping gene.
ELISA
Ninety-six-well MaxiSorp plates were coated over night
at 4°C with 1 μg/mL of the receptors ACVR2A and
ACVR2B in PBS. The wells were blocked for one hour at
Olsen et al. Cell Communication and Signaling  (2015) 13:27 Page 6 of 7
room temperature with 1% BSA (R&D Systems) in PBS
before addition of BMP-9, activin A, follistatin or combi-
nations of these. Bound BMP-9 was detected using detec-
tion reagents from BMP-9 DuoSet ELISA (R&D Systems),
and optical density was determined using iMark™ Micro-
plate Absorbance Reader (Bio-Rad, Hercules, CA, USA).
Statistics
Statistical calculations were done using GraphPad Prism
6 (GraphPad Software, Inc., La Jolla, CA, USA). Signifi-
cance was analyzed using two-sided, unpaired T-test
with Welch’s correction. Differences of P < 0.05 or **P <
0.01 were considered significant.
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Additional file 1: Olsen OE et al. Activin A inhibits BMP-signaling by
binding ACVR2A and ACVR2B. The effect of activin A is also seen in
the JJN-3 IL-6 independent cell line. JJN-3 cells were treated for one hour
with BMP-6 (100 ng/mL) or BMP-9 (5 ng/mL) with or without activin A
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BMP-9 in myeloma cells. (A) IH-1 cells were treated for three days with
BMP-2 (5 ng/mL), BMP-4 (2.5 ng/mL), BMP-6 (25 ng/mL) and BMP-9
(0.5 ng/mL), and with or without TGF-β (5 ng/mL) before cell growth was
determined. The CellTiter Glo assay was used and relative luciferase units
(RLU) reflected the amount of ATP in each well. Error bars represent +/−1 SD
of three technical replicates. (B) Immunoblotting was used to determine
phosphorylation of SMAD1/5/8 and SMAD2 in IH-1 cells treated for 4 hours
with activin A (10 ng/ml) or TGF-β (5 ng/mL) with or without BMP-6
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(C) Effect of the inhibitor SB431542 (5 μM) was shown with immunoblotting
of IH-1 cells treated with activin A (10 ng/ml) or TGF-β (5 ng/mL).
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